Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme
Affiliations
- PMID: 1965907
Item in Clipboard
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme
J Neurosurg Sci.
1990 Jul-Dec.
Abstract
Adherent lymphokine-activated killer (A-LAK) activity has been recently differentiated in recombinant interleukin-2 (rIL-2) activated PBL. A pilot study on A-LAK + rIL-2 injection into the post-surgical cavity of glioblastoma-operated patients is ongoing. Preliminary data support the feasibility of this technique, which may improve the antitumor response of the host.
Similar articles
-
Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.Cancer. 1988 Aug 15;62(4):665-71. doi: 10.1002/1097-0142(19880815)62:4<665::aid-cncr2820620403>3.0.co;2-o. Cancer. 1988. PMID: 2840186
-
Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.J Immunother. 2009 Nov-Dec;32(9):914-9. doi: 10.1097/CJI.0b013e3181b2910f. J Immunother. 2009. PMID: 19816190 Clinical Trial.
-
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.Cancer Immunol Immunother. 1994 Sep;39(3):193-7. doi: 10.1007/BF01533386. Cancer Immunol Immunother. 1994. PMID: 7923250 Free PMC article. Clinical Trial.
-
Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.Allergol Immunopathol (Madr). 1991 Sep-Oct;19(5):209-14. Allergol Immunopathol (Madr). 1991. PMID: 1811418 Review. No abstract available.
-
The cellular immunotherapy of primary brain tumors.Rev Neurol (Paris). 1992;148(6-7):454-66. Rev Neurol (Paris). 1992. PMID: 1448666 Review.
MeSH terms
Substances
LinkOut - more resources
Medical